The latest therapeutic agents for diabetic nephropathy include glucagon-like peptide receptor agonists and sodium-glucose cotransporter protein 2 inhibitors. Glucagon-like peptide receptor agonists, also known as GLP1RA, are a new type of hypoglycemic drug. Its mechanism of action is to act on pancreatic β-cells to promote insulin synthesis and secretion. Sodium-glucose co-transporter protein 2 inhibitor, also known as SGLT-2. can inhibit the reabsorption of glucose by the kidneys, so that excess glucose is excreted from the urine, lowering blood glucose. Clinical studies of the above two drugs have found that they can lower glucose at the same time, can reduce the rate of decline in glomerular filtration rate and reduce the production of urine protein. It is recommended that patients with diabetic nephropathy should go to the hospital in time for consultation and active treatment under the guidance of the doctor, and do not use medication on their own.